Latest Eisai Stories
WOODCLIFF LAKE, N.J., April 30, 2015 /PRNewswire/ -- Eisai Inc. and Eisai Co., Ltd.
RnRMarketResearch.com adds “Metastatic Ovarian Cancer – Pipeline Review, H1 2015” to its store.
RnRMarketResearch.com adds “Dermatitis – Pipeline Review, H1 2015” to its store.
DUBLIN, April 20, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zbfftz/cns_therapeutics) has announced the addition of the "CNS
DALLAS, April 16, 2015 /PRNewswire/ -- RnRMarketResearch.com adds 2015 EpiCast Report on Alzheimer's Disease - Epidemiology Forecast to 2023 of 82 pages to the Alzheimer
LUGANO, Switzerland and WOODCLIFF LAKE, N.J., April 15, 2015 /PRNewswire/ -- Helsinn Group and Eisai Inc.
-- New Drug Application for once-daily formulation of lorcaserin expected to be submitted to the FDA later this year -- WOODCLIFF LAKE, N.J.
WOODCLIFF LAKE, N.J., April 9, 2015 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States.
Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
RnRMarketResearch.com adds “Arterial Thrombosis – Pipeline Review, H1 2015” report to its store.